$62.95
1.27% yesterday
Nasdaq, Dec 02, 10:00 pm CET

Bio-Techne Corporation Stock price

$62.95
+1.69 2.76% 1M
+14.34 29.50% 6M
-9.08 12.61% YTD
-13.07 17.19% 1Y
-21.74 25.67% 3Y
-11.63 15.60% 5Y
+39.95 173.67% 10Y
+48.82 345.58% 20Y
Nasdaq, Closing price Tue, Dec 02 2025
-0.81 1.27%

New AI Insights on Bio-Techne Corporation Insights AI Insights on Bio-Techne Corporation

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$9.9b
Enterprise Value
$10.1b
Net debt
$155.0m
Cash
$145.0m
Shares outstanding
155.8m
Valuation (TTM | estimate)
P/E
132.8 | 31.2
P/S
8.2 | 7.9
EV/Sales
8.3 | 8.0
EV/FCF
45.0
P/B
5.1
Dividends
DPS
$0.32
Yield 1Y | 5Y
0.5% | 0.4%
Growth 1Y | 5Y
0.0% | 0.0%
Payout 1Y | 3Y
69.6% | 29.4%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$1.2b | $1.3b
EBITDA
$375.3m | $450.6m
EBIT
$269.2m | $411.1m
Net Income
$76.8m | $318.3m
Free Cash Flow
$224.1m
Growth (TTM | estimate)
Revenue
-16.0% | 3.6%
EBITDA
-9.0% | 51.9%
EBIT
-10.6% | 54.9%
Net Income
-61.9% | 333.9%
Free Cash Flow
-8.6%
Margin (TTM | estimate)
Gross
66.8%
EBITDA
30.9% | 35.7%
EBIT
22.1%
Net
6.3% | 25.2%
Free Cash Flow
18.4%
Financial Health
Equity Ratio
75.0%
Return on Equity
3.8%
ROCE
11.3%
ROIC
8.5%
Debt/Equity
0.2
More
EPS
$0.5
FCF per Share
$1.4
Short interest
6.8%
Employees
3k
Rev per Employee
$390.0k
Show more

Is Bio-Techne Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,078 stocks worldwide.

Bio-Techne Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Bio-Techne Corporation forecast:

18x Buy
78%
5x Hold
22%

Analyst Opinions

23 Analysts have issued a Bio-Techne Corporation forecast:

Buy
78%
Hold
22%

Financial data from Bio-Techne Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
1,217 1,217
16% 16%
100%
- Direct Costs 404 404
18% 18%
33%
813 813
15% 15%
67%
- Selling and Administrative Expenses 444 444
17% 17%
36%
- Research and Development Expense 100 100
17% 17%
8%
375 375
9% 9%
31%
- Depreciation and Amortization 106 106
5% 5%
9%
EBIT (Operating Income) EBIT 269 269
11% 11%
22%
Net Profit 77 77
62% 62%
6%

In millions USD.

Don't miss a Thing! We will send you all news about Bio-Techne Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bio-Techne Corporation Stock News

Neutral
Seeking Alpha
about 7 hours ago
Bio-Techne Corporation (TECH) Presents at Evercore 8th Annual Healthcare Conference Transcript
Neutral
PRNewsWire
8 days ago
MINNEAPOLIS , Nov. 25, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: 8th Annual Evercore Healthcare Conference 2025 December 2, 2025 8:20 AM EST Citi's 2025 Global Healthcare Conference December 3, 2025 3:15 PM EST 53rd Annual Nasdaq Investor Conference December 9, 2025 9:30 AM GMT A live webcast of the pre...
Neutral
Seeking Alpha
13 days ago
Bio-Techne Corporation ( TECH ) Jefferies London Healthcare Conference 2025 November 20, 2025 7:30 AM EST Company Participants James Hippel - Executive VP of Finance & CFO Conference Call Participants Tycho Peterson Tycho Peterson Presentation Tycho Peterson Okay. Great. We're going to kick it off.
More Bio-Techne Corporation News

Company Profile

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Biotechnology, Protein Platforms, Diagnostics, and Corporate. The Biotechnology segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and related reagents, as well as in situ hybridization, media and other cell culture products and reagents to the biotechnology research community. The Protein Platforms segment develops, manufactures, and sells tools to simplify protein analysis. The Diagnostics segment includes blood chemistry and blood gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market worldwide. The company was founded on 1976 and is headquartered in Minneapolis, MN.

Head office United States
CEO Kim Kelderman
Employees 3,100
Founded 1976
Website www.bio-techne.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today